Last Updated on September 28, 2021 by The Health Master
Download notification regarding Heparin Injection: The pharmaceutical industry has urged National Pharmaceuticals Pricing Authority (NPPA) to extend the revised ceiling price of Heparin injection till March 31, 2022 to ensure consistent availability of the product amid its high demand and exorbitant prices of its raw material imported from China.
Meanwhile NPPA has issued a notification on dated 23-09-2021.
NPPA by invoking its extraordinary powers in public interest increased the ceiling prices of Heparin injection 1000IU/ml and Heparin injection 5000IU/ml by 50 per cent vide notification S.O. 2151(E) dated June 30, 2020. This proved to be a savior to manufacturers of the product.
Being an essential medicine for treatment in the ongoing pandemic situation, NPPA decided to continue with the increased ceiling price and the said notification was extended vide another notification no. S.O. 4333 (E) dated December 3, 2020 till March 31, 2021 and further extended vide notification no. S.O. 1236 (E) dated March 17, 2021 till September 30, 2021
Apart from being an essential treatment in the Covid-19 scenario, Heparin still remains the front-line drug and lifesaving drug used for dialysis in case of kidney failure. This in turn has resulted in a higher demand for the product.
NPPA’s thoughtful step of granting extension of revised ceiling price of the product enabled the manufacturers to put up with such high demand. The issue of high prices of API continues to haunt the manufacturers of the product due to which many of the manufacturers are unable to sustain in this particular scenario where the demand of the product is equally high.
Besides, several manufacturers of the product are still operating at a huge loss to manufacture and supply the product due to the continuing increase in the import price of API imported from China, stated Indian Drug Manufacturers’ Association (IDMA) in its representation to NPPA seeking extension of revised ceiling prices of Heparin injection for six months.
The pandemic has brought extreme hardship to the entire industry and the impact of the pandemic situation is anticipated to stay in the market for some time before the situation moves towards normalcy. Striking a balance between the availability of the product and extending requisite support to the manufacturers is the panacea for ensuring the well-being of our population, the industry body said.
Therefore, in order to ensure uninterrupted supply of the product amid rise in prices of Heparin sodium which constitutes to be a quintessential portion of the input cost, there is a dire need to extend the revised ceiling price of the product beyond September 30, 2021 till March 31, 2022, it added.
IDMA has received several representations from the drug manufacturers urging it to request NPPA to extend the validity of the revised ceiling price of the product beyond the notified period i.e. September 30, 2021 so as to sustain themselves during the ongoing pandemic situation.